Pharming Group N.V. announces that a new diagnosis code for reporting cases of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be added to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) by the US Centers for Disease Control and Prevention (CDC). The diagnosis code, D81.82 ‒ Activated Phosphoinositide 3-kinase Delta Syndrome (APDS), will be effective starting October 1, 2022.

Pharming Group N.V. announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib. Leniolisib has been studied for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents age 12 or older in the European Economic Area (EEA). Pharming is on track and plans to submit its MAA for leniolisib to the EMA in October 2022.

Pharming confirms it will announce financial results for the six months ended 30 June 2022 on Thursday, August 4, 2022.

Pharming announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference 2022, a hybrid meeting based in New York, at 22:00-22:30 CET/16:00-16:30 EDT on 9 June 2022.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.  

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022.

Pharming confirms it will announce financial results for the first quarter of the year ended 31 March 2022 on Thursday, 12 May 2022.

An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children. A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA’s Early Access to Medicines Scheme

Following an agreed investment by European investment company Gimv, Pharming’s minority stake of 43.85% in BioConnection will reduce to 22.98%. As a result of this transaction, Pharming will receive one-off US$ 7.5 million (EUR 6.9 million) net cash proceeds.

Pharming announces the filing of its Annual Report for the year ended 31 December 2021. The Company has also filed its Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the same period. In addition, the company convenes its 2022 AGM.